Very exciting research for neuroregenerative therapy. This stem cell procedure does not use chemotherapy or immune cell ablation first---it is a novel approach, not done anywhere else just yet. The Phase II trial will be a double-blind, placebo-controlled, randomized trial with forty patients in a crossover design. Stem cells are taken from the patient’s bone marrow and manipulated to become brain-like neural cells, a process created and found only at Tisch MSRCNY. All treatments and research will be conducted at the Tisch MS Research Center of New York and will expand to include an additional leading MS center. A few patients, not all, saw benefits of the treatment in Phase 1.

Stem Cells Show Reversal of Disability in Multiple Sclerosis
at the American Academy of Neurology (AAN) 2016 Annual Meeting
MS Patients Take Steps without Cane as Damage is Repaired

Read the full press release here:
http://www.tischms.org/news/stem-cells-show-reversal-disability-multiple-sclerosis-american-academy-neurology-aan-2016